Abstract
A single dose of 150 mg fluconazole was used to treat 180 patients with clinical and mycological evidence of vaginal candidiasis in an open, non-comparative, multicentre trial. The clinical response to treatment was excellent, with 97 % of patients cured or markedly improved after 5 to 16 days. At long-term assessment (27 to 62 days), the proportion cured was 88 %. Candida was eradicated from the vagina in 93 % of patients at short-term assessment and in 73 % at long-term assessment. The rate of relapse, reinfection or recolonization at long-term assessment in patients who had responded at short-term assessment was 23 %. The incidence of side-effects was low, and consisted mainly of mild gastrointestinal complaints. Abnormal laboratory test results occurred in 15 of 167 evaluable patients, but all were minor and of minimal clinical significance. Oral fluconazole given in a single dose of 150 mg is an effective, safe and well tolerated treatment for vaginal candidiasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bisschop, M. P. J. M., Merkus, J. M. W. M., Scheygrond, H., Van Cutsem, J., Van de Kuy, A. Treatment of vaginal candidiasis with ketoconazole, a new orally active antimycotic. European Journal of Obstetrics, Gynaecology, and Reproductive Biology 1979, 9: 253–258.
Van der Pas, H., Peeters, F., Janssens, D., Schauwaert, E., Van Cutsem, J. Treatment of vaginal candidiasis with oral ketoconazole. European Journal of Obstetrics, Gynaecology, and Reproductive Biology 1983, 14: 399–404.
Pont, A., Williams, P. L., Loose, D. S., Feldman, D., Reitz, R. E., Bochra, C., Stevens, D. A. Ketoconazole blocks adrenal steroid synthesis. Annals of Internal Medicine 1982, 97: 370–372.
Hawkins Van Tyle, J. Ketoconazole. Pharmacotherapy 1984, 4: 343–373.
Janssen, P. A. J., Symeons, J. E. Hepatic reactions during ketoconazole treatment. American Journal of Medicine 1983, 74: 80–85.
Richardson, K., Brammer, K. W., Marriott, M. S., Troke, P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections withCandida albicans andTrichophyton mentagrophytes. Antimicrobial Agents and Chemotherapy 1985, 27: 832–835.
Humphrey, M. J., Jevons, S., Tarbit, M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrobial Agents and Chemotherapy 1985, 28: 648–653.
Faccini, J. M., Bennett, P. N., Reid, J. L. European ethical review committee: the experience of an international ethics committee reviewing protocols for drug trials. British Medical Journal 1984, 289: 1052–1054.
Miles, M. R., Olsen, L., Rogers, A. Recurrent vaginal candidiasis. Importance of an intestinal reservoir. Journal of the American Medical Association 1977, 238: 1836–1837.
Author information
Consortia
Additional information
The following persons participated in the study: P. E. Lebech, Copenhagen, Denmark; N. C. Nielsen, Copenhagen, Denmark; F. Lundvall, Hvidovre, Denmark; E. Thane, Slagelse, Denmark; S. Larsen, Valby, Denmark; T. von Herbst, Copenhagen, Denmark; S. Lie, Haugesund, Norway; T. Saltveit, Haugesund, Norway; O. Sande, Hamar, Norway; J. Choukroun, Puteaux, France; R. Renaud, Strasbourg, France; G. Kleiber, Grobenzell, FRG; K. W. Brammer, Sandwich, UK.
Responsible author: K. W. Brammer, Pfizer Central Research, Ramsgate Road, Sandwich, Kent, UK.
Rights and permissions
About this article
Cite this article
Multicentre Study Group. Treatment of vaginal candidiasis with a single oral dose of fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 7, 364–367 (1988). https://doi.org/10.1007/BF01962338
Issue Date:
DOI: https://doi.org/10.1007/BF01962338